CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech that has proved helpful vigilantly but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, along with Vyrologix. In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of possible […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful vigilantly but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn's inventories of leronlimab are building up, whether they will ever be used is an open question.


While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn post, "CytoDyn: What In order to Do When It's Too Good to be able to Be True?", set away all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire job interview that I came away with an inadequate impression of the company.

Irony of irony, my bad opinion of the business enterprise has grown steadily, however, the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today's transaction of $3.5 million transfers ownership of the expertise as well as associated intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance.... milestone payments upon commencement of a stage III clinical trial ($1.5 million) plus the first brand new drug program endorsement ($five million), and even royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn's guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and many therapies, it's this individual treatments as well as a "broad pipeline of indications" because it puts it. I call some pipelines, "pipedots." In CytoDyn's situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, several illness sorts, multiple delivering presentations and multiple publications.

Can all this be smoke cigarettes and mirrors? That's a question I've been asking myself through the very start of my interest in this particular organization. Judging by the multiples of a huge number of several remarks on listings accessible via Seeking Alpha's CytoDyn Summary page, I am much from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *